Gonul Hazal Koc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gonul Hazal Koc has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Jolanda Jacoba Luime
Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
8 shared publications - Marc Redwart Kok
Department of Rheumatology, Maasstad Hospital, Rotterdam, The Netherlands
8 shared publications - Selinde Snoeck Henkemans
Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands
6 shared publications - Marijn Vis
Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
5 shared publications Paul Baudoin
Department of Rheumatology, Reumazorg Zuid West Nederland, Goes, The Netherlands
5 shared publications- Ilja Tchetverikov
Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands
4 shared publications
Latest Publications
- Open Access
Beyond disease activity: patient-reported impact of disease states in psoriatic arthritis using PsAID-12 time-independent clustering
The lived experience of psoriatic arthritis (PsA) is heterogeneous and not fully captured by conventional disease activity measures. This study aimed to identify data-driven patient-reported impact of disease states using the 12-item Psoriatic Arthritis Impact of Disease questionnaire (PsAID-12) responses and to assess their clinical relevance. 5099 observations from 880 participants in the Dutch southwest Early Psoriatic Arthritis (DEPAR) cohort were analysed. Multiple clustering techniques were applied to PsAID-12 domain scores to derive impact states independently of time. The final clustering solution was selected based on cohesion, separation, stability under data perturbation and clinical interpretability. Clusters were characterised based on symptom/impact profiles and evaluated against clinical disease activity and established disease activity states (Disease Activity in PSoriatic Arthritis, Psoriatic Arthritis Disease Activity Score, Minimal Disease Activity, PsAID-12). Transitions between states were examined afterwards. Six impact of disease states were identified, ranging from very mild to pervasively severe burden. Among states with comparable impact severity, skin problems and psychosocial burden were the primary differentiators. Remission and low disease activity corresponded strongly with (very) mild impact clusters, whereas moderate and high disease activity showed wide dispersion across all clusters. Patients in extreme states showed greater temporal stability, while intermediate states exhibited greater transition dynamics, typically to adjacent clusters. PsA comprises distinct lived-experience states not fully captured by traditional treatment targets. Patients with similar clinical disease activity may experience markedly different levels and types of impact. Findings highlight the importance of dermatological, emotional and social dimensions in addition to musculoskeletal inflammation. Integrating patient-reported symptom and impact assessments into routine evaluation may facilitate more tailored treatment strategies.
Open AccessBeyond disease activity: patient-reported impact of disease states in psoriatic arthritis using PsAID-12 time-independent clustering
The lived experience of psoriatic arthritis (PsA) is heterogeneous and not fully captured by conventional disease activity measures. This study aimed to identify data-driven patient-reported impact of disease states using the 12-item Psoriatic Arthritis Impact of Disease questionnaire (PsAID-12) responses and to assess their clinical relevance. 5099 observations from 880 participants in the Dutch southwest Early Psoriatic Arthritis (DEPAR) cohort were analysed. Multiple clustering techniques were applied to PsAID-12 domain scores to derive impact states independently of time. The final clustering solution was selected based on cohesion, separation, stability under data perturbation and clinical interpretability. Clusters were characterised based on symptom/impact profiles and evaluated against clinical disease activity and established disease activity states (Disease Activity in PSoriatic Arthritis, Psoriatic Arthritis Disease Activity Score, Minimal Disease Activity, PsAID-12). Transitions between states were examined afterwards. Six impact of disease states were identified, ranging from very mild to pervasively severe burden. Among states with comparable impact severity, skin problems and psychosocial burden were the primary differentiators. Remission and low disease activity corresponded strongly with (very) mild impact clusters, whereas moderate and high disease activity showed wide dispersion across all clusters. Patients in extreme states showed greater temporal stability, while intermediate states exhibited greater transition dynamics, typically to adjacent clusters. PsA comprises distinct lived-experience states not fully captured by traditional treatment targets. Patients with similar clinical disease activity may experience markedly different levels and types of impact. Findings highlight the importance of dermatological, emotional and social dimensions in addition to musculoskeletal inflammation. Integrating patient-reported symptom and impact assessments into routine evaluation may facilitate more tailored treatment strategies.
- Open Access
Frequency of complex-to-manage, difficult-to-manage and treatment-refractory psoriatic arthritis: applying the 2025 GRAPPA and EULAR definitions in a real-world longitudinal PsA cohort
Objectives: To determine the frequency and baseline characteristic differences of complex-to-manage (C2M), difficult-to-manage (D2M) and treatment-refractory (TR) psoriatic arthritis (PsA) in a real-world longitudinal cohort, using the recently proposed 2025 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) definitions. Methods: We analysed data from newly diagnosed, disease-modifying antirheumatic drug-naïve patients with PsA enrolled in the Dutch Southwest Early Psoriatic Arthritis cohort between 2013 and 2023. Patients were classified using the 2025 GRAPPA (C2M, TR) and EULAR (D2M, TR) PsA definitions. Frequencies were calculated for each definition. Time-to-event analyses using Kaplan-Meier methods assessed the timing of definition fulfilment and individual components. Longitudinal differences in patient-reported outcomes (PROs) were assessed using linear mixed-effects models. Results: Among 885 newly diagnosed patients with PsA, 20% (179/885) fulfilled the GRAPPA-C2M definition, 4.2% (37/885) fulfilled the EULAR-D2M definition, 3.8% (34/885) met the EULAR-TR and 1.2% (11/885) fulfilled the GRAPPA-TR criteria definition during follow-up. Female sex, higher body mass index (BMI), longer symptom duration, presence of enthesitis and greater skin involvement differed with meeting definitions at baseline. Patients classified as GRAPPA-C2M, GRAPPA-TR, EULAR-D2M and EULAR-TR consistently reported worse long-term PROs (Health Assessment Questionnaire-Disability Index scores in C2M (β=0.17, 95% CI 0.10 to 0.24), GRAPPA-TR (β=0.37, 95% CI 0.22 to 0.51), EULAR-D2M (β=0.36, 95% CI 0.20 to 0.48) and EULAR-TR (β=0.40, 95% CI 0.25 to 0.55)). Conclusions: Approximately 20% of patients with early PsA fulfilled the GRAPPA-C2M criteria, representing the earliest and broadest subgroup, while 4% met EULAR-D2M/EULAR-TR and 1.2% GRAPPA-TR definitions. These latter subgroups were more likely to be female, had higher BMI, greater skin involvement and enthesitis and experienced persistently worse PROs, underscoring the need for tailored management strategies.
Open AccessFrequency of complex-to-manage, difficult-to-manage and treatment-refractory psoriatic arthritis: applying the 2025 GRAPPA and EULAR definitions in a real-world longitudinal PsA cohort
Objectives: To determine the frequency and baseline characteristic differences of complex-to-manage (C2M), difficult-to-manage (D2M) and treatment-refractory (TR) psoriatic arthritis (PsA) in a real-world longitudinal cohort, using the recently proposed 2025 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) definitions. Methods: We analysed data from newly diagnosed, disease-modifying antirheumatic drug-naïve patients with PsA enrolled in the Dutch Southwest Early Psoriatic Arthritis cohort between 2013 and 2023. Patients were classified using the 2025 GRAPPA (C2M, TR) and EULAR (D2M, TR) PsA definitions. Frequencies were calculated for each definition. Time-to-event analyses using Kaplan-Meier methods assessed the timing of definition fulfilment and individual components. Longitudinal differences in patient-reported outcomes (PROs) were assessed using linear mixed-effects models. Results: Among 885 newly diagnosed patients with PsA, 20% (179/885) fulfilled the GRAPPA-C2M definition, 4.2% (37/885) fulfilled the EULAR-D2M definition, 3.8% (34/885) met the EULAR-TR and 1.2% (11/885) fulfilled the GRAPPA-TR criteria definition during follow-up. Female sex, higher body mass index (BMI), longer symptom duration, presence of enthesitis and greater skin involvement differed with meeting definitions at baseline. Patients classified as GRAPPA-C2M, GRAPPA-TR, EULAR-D2M and EULAR-TR consistently reported worse long-term PROs (Health Assessment Questionnaire-Disability Index scores in C2M (β=0.17, 95% CI 0.10 to 0.24), GRAPPA-TR (β=0.37, 95% CI 0.22 to 0.51), EULAR-D2M (β=0.36, 95% CI 0.20 to 0.48) and EULAR-TR (β=0.40, 95% CI 0.25 to 0.55)). Conclusions: Approximately 20% of patients with early PsA fulfilled the GRAPPA-C2M criteria, representing the earliest and broadest subgroup, while 4% met EULAR-D2M/EULAR-TR and 1.2% GRAPPA-TR definitions. These latter subgroups were more likely to be female, had higher BMI, greater skin involvement and enthesitis and experienced persistently worse PROs, underscoring the need for tailored management strategies.
- 21 November 2025
- Published by Elsevier in The Lancet Rheumatology
- Vol. 8 (1) , e23-e32
Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies
- 21 November 2025
- Published by Elsevier in The Lancet Rheumatology
- Vol. 8 (1) , e23-e32
Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies
- Open Access
- 16 May 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (7) , 1130-1139
Disease-modifying antirheumatic drug–free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study
- 16 May 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (7) , 1130-1139
Open AccessDisease-modifying antirheumatic drug–free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study
- 15 May 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
The Effect of Early Attainment of Minimal Disease Activity on Radiographic Outcomes: A Real-World Longitudinal Cohort Study in Psoriatic Arthritis
Objective: To evaluate the effect of achieving minimal disease activity (MDA) within the first year on radiologic damage at 3-year follow-up in patients with newly diagnosed psoriatic arthritis (PsA).Methods: Data were used from the Dutch southwest Early PsA cohort, a real-world cohort of newly diagnosed patients with PsA, focusing on those with oligoarthritis or polyarthritis. Patients were stratified into 3 groups: (1) sustained MDA, achieving MDA at least at both 9 and 12 months post diagnosis; (2) nonsustained MDA, achieving MDA in the first year but not sustaining it at 9 and 12 months; (3) no MDA, not achieving MDA in the first year. Radiographic assessment was used by the modified Total Sharp/van der Heijde score for PsA. Group comparisons at 3-year follow-up for radiographic changes were conducted using a linear mixed model.Results: Two hundred eighty-four patients were categorized into 3 groups: 96 patients (34%) in the sustained MDA group, 83 (29%) in the nonsustained MDA group, and 105 (37%) in the no-MDA group. According to baseline characteristics, in the no-MDA group, a notably higher rate of female individuals (70%) and an elevated tender joint count (median 7, IQR 4-12) were observed. Patients who did not achieve MDA in the first year experienced remarkably higher radiographic changes during follow-up than the sustained MDA group (β 0.05, 95% CI 0.02-0.08,P< 0.01).Conclusion: Radiographic changes during the 3-year follow-up were markedly higher in those unable to achieve MDA within the first year of follow-up, emphasizing the long-term structural benefits of reaching stringent disease activity targets early in the disease course.
- 15 May 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
The Effect of Early Attainment of Minimal Disease Activity on Radiographic Outcomes: A Real-World Longitudinal Cohort Study in Psoriatic Arthritis
Objective: To evaluate the effect of achieving minimal disease activity (MDA) within the first year on radiologic damage at 3-year follow-up in patients with newly diagnosed psoriatic arthritis (PsA).Methods: Data were used from the Dutch southwest Early PsA cohort, a real-world cohort of newly diagnosed patients with PsA, focusing on those with oligoarthritis or polyarthritis. Patients were stratified into 3 groups: (1) sustained MDA, achieving MDA at least at both 9 and 12 months post diagnosis; (2) nonsustained MDA, achieving MDA in the first year but not sustaining it at 9 and 12 months; (3) no MDA, not achieving MDA in the first year. Radiographic assessment was used by the modified Total Sharp/van der Heijde score for PsA. Group comparisons at 3-year follow-up for radiographic changes were conducted using a linear mixed model.Results: Two hundred eighty-four patients were categorized into 3 groups: 96 patients (34%) in the sustained MDA group, 83 (29%) in the nonsustained MDA group, and 105 (37%) in the no-MDA group. According to baseline characteristics, in the no-MDA group, a notably higher rate of female individuals (70%) and an elevated tender joint count (median 7, IQR 4-12) were observed. Patients who did not achieve MDA in the first year experienced remarkably higher radiographic changes during follow-up than the sustained MDA group (β 0.05, 95% CI 0.02-0.08,P< 0.01).Conclusion: Radiographic changes during the 3-year follow-up were markedly higher in those unable to achieve MDA within the first year of follow-up, emphasizing the long-term structural benefits of reaching stringent disease activity targets early in the disease course.
- Top Cited Papers
- 1 March 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (6) , 553-562
Sex Differences in Rheumatoid Arthritis: New Insights From Clinical and Patient-Reported Outcome Perspectives
Objective: The disease course and burden of rheumatoid arthritis (RA) may differ between female and male individuals, but existing data on these differences are limited and often contradictory. Therefore, we investigated whether clinical outcomes and patient-reported outcomes (PROs) differ between female and male patients with RA over time. Methods: All female (n = 286) and male (n = 139) patients with RA according to 1987 and/or 2010 criteria from Treatment in the Rotterdam Early Arthritis Cohort (tREACH), a stratified single-blinded trial with a treat-to-target (T2T) approach and fixed medication protocol, were included. Clinical outcomes include disease activity, medication usage, sustained disease-modifying antirheumatic drug (DMARD)-free remission (SDFR), and radiographic progression. In addition, the following PROs were investigated: general health, pain, functional ability, health-related quality of life, fatigue, productivity loss, and a possible depression or anxiety disorder. For comparisons over time, a mixed model or Cox proportional hazard model was used. The mixed models were adjusted for age, initial treatment, and disease activity (Disease Activity Score in 44 joints [DAS44]). Results: Female patients had a higher DAS44 over time compared to male patients (β 0.36, 95% CI 0.25-0.47, P < 0.001), which also resulted in more treatment adjustments including use of biologic DMARDs (bDMARDs; 36% vs 24%, P < 0.001). Although not significant, first bDMARD survival seemed shorter in female patients (hazard ratio [HR] 1.4, 95% CI 0.8-2.6, P = 0.24). However, no differences were found in SDFR and radiographic progression. With regard to PROs, only functional ability differed significantly between sexes after adjusting for confounders, including disease activity (Health Assessment Questionnaire–Disability Index, β 0.10, 95% CI 0.04-0.17, P < 0.001). Conclusion: Clinical outcomes and PROs are intertwined, and both improve with a T2T management approach. Nevertheless, female patients with RA have higher disease activity, a greater need for bDMARDs—although these have lower efficacy—and more functional impairment over time, underscoring the need for sex-specific management recommendations. (Trial registration number: ISRCTN26791028 )
- 1 March 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (6) , 553-562
Top Cited PapersSex Differences in Rheumatoid Arthritis: New Insights From Clinical and Patient-Reported Outcome Perspectives
Objective: The disease course and burden of rheumatoid arthritis (RA) may differ between female and male individuals, but existing data on these differences are limited and often contradictory. Therefore, we investigated whether clinical outcomes and patient-reported outcomes (PROs) differ between female and male patients with RA over time. Methods: All female (n = 286) and male (n = 139) patients with RA according to 1987 and/or 2010 criteria from Treatment in the Rotterdam Early Arthritis Cohort (tREACH), a stratified single-blinded trial with a treat-to-target (T2T) approach and fixed medication protocol, were included. Clinical outcomes include disease activity, medication usage, sustained disease-modifying antirheumatic drug (DMARD)-free remission (SDFR), and radiographic progression. In addition, the following PROs were investigated: general health, pain, functional ability, health-related quality of life, fatigue, productivity loss, and a possible depression or anxiety disorder. For comparisons over time, a mixed model or Cox proportional hazard model was used. The mixed models were adjusted for age, initial treatment, and disease activity (Disease Activity Score in 44 joints [DAS44]). Results: Female patients had a higher DAS44 over time compared to male patients (β 0.36, 95% CI 0.25-0.47, P < 0.001), which also resulted in more treatment adjustments including use of biologic DMARDs (bDMARDs; 36% vs 24%, P < 0.001). Although not significant, first bDMARD survival seemed shorter in female patients (hazard ratio [HR] 1.4, 95% CI 0.8-2.6, P = 0.24). However, no differences were found in SDFR and radiographic progression. With regard to PROs, only functional ability differed significantly between sexes after adjusting for confounders, including disease activity (Health Assessment Questionnaire–Disability Index, β 0.10, 95% CI 0.04-0.17, P < 0.001). Conclusion: Clinical outcomes and PROs are intertwined, and both improve with a T2T management approach. Nevertheless, female patients with RA have higher disease activity, a greater need for bDMARDs—although these have lower efficacy—and more functional impairment over time, underscoring the need for sex-specific management recommendations. (Trial registration number: ISRCTN26791028 )
- Open Access
- 6 November 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2411-2421
Association between depression and anxiety and inability to achieve remission in rheumatoid arthritis and psoriatic arthritis
Objectives: To investigate the association between depression and anxiety and the inability to achieve remission in RA and PsA patients. In addition, the association between depressive and anxiety symptoms and disease activity components was explored. Methods: A total of 400 RA and 367 PsA patients from the tREACH and DEPAR were included, respectively. Patients had a possible depression or anxiety disorder if they scored >7 on the Hospital Anxiety and Depression Scale (HADS). Remission was defined as DAS44 <1.6 in RA and DAPSA ≤ 4 in PsA. Mixed models were used to assess the association between depression/anxiety, at any timepoint during 2 years, and remission during 2 years, and to explore which disease activity components are most influenced by depression/anxiety. Results: At baseline, 20% of RA patients had a possible depression and 30% a possible anxiety disorder. In PsA this was 18% and 23%. After adjustment for concurrent anxiety symptoms, depression was associated with a lower odds of achieving remission during 2 years of follow-up [OR 0.45 (95%CI 0.25–0.80) for RA and OR 0.24 (95%CI 0.08–0.71) for PsA]. Anxiety was not associated with remission after adjustment for concurrent depression symptoms. The presence of depression/anxiety was associated with higher tender joint count, worse general health, more pain and slightly elevated inflammation markers, but not with more swollen joints in both RA and PsA. Conclusion: The presence of depressive symptoms in RA and PsA patients at baseline or during follow-up was associated with a lower likelihood of achieving remission. Healthcare professionals should, therefore, be aware of symptoms of depression.
- 6 November 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2411-2421
Open AccessAssociation between depression and anxiety and inability to achieve remission in rheumatoid arthritis and psoriatic arthritis
Objectives: To investigate the association between depression and anxiety and the inability to achieve remission in RA and PsA patients. In addition, the association between depressive and anxiety symptoms and disease activity components was explored. Methods: A total of 400 RA and 367 PsA patients from the tREACH and DEPAR were included, respectively. Patients had a possible depression or anxiety disorder if they scored >7 on the Hospital Anxiety and Depression Scale (HADS). Remission was defined as DAS44 <1.6 in RA and DAPSA ≤ 4 in PsA. Mixed models were used to assess the association between depression/anxiety, at any timepoint during 2 years, and remission during 2 years, and to explore which disease activity components are most influenced by depression/anxiety. Results: At baseline, 20% of RA patients had a possible depression and 30% a possible anxiety disorder. In PsA this was 18% and 23%. After adjustment for concurrent anxiety symptoms, depression was associated with a lower odds of achieving remission during 2 years of follow-up [OR 0.45 (95%CI 0.25–0.80) for RA and OR 0.24 (95%CI 0.08–0.71) for PsA]. Anxiety was not associated with remission after adjustment for concurrent depression symptoms. The presence of depression/anxiety was associated with higher tender joint count, worse general health, more pain and slightly elevated inflammation markers, but not with more swollen joints in both RA and PsA. Conclusion: The presence of depressive symptoms in RA and PsA patients at baseline or during follow-up was associated with a lower likelihood of achieving remission. Healthcare professionals should, therefore, be aware of symptoms of depression.
- Open Access
Combining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritis
Objectives To investigate whether a combination of general health (Visual Analogue Scale (VAS)), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain (VAS/Numerical Rating Scale (NRS)), quality of life (EQ-5D), fatigue (VAS/NRS) and presenteeism (0%–100% productivity loss) could aid as a screening tool to detect active disease in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Methods RA patients from the tREACH trial and TARA trial (n=683) and PsA patients from the DEPAR cohort (n=525) were included. The association of a deterioration in the aforementioned patient-reported outcome measure (PROM) scores between two consecutive visits and having active disease was assessed. Active disease was defined as a change from disease activity score (DAS) ≤2.4 to DAS >2.4 in RA or Disease Activity Index in Psoriatic Arthritis (DAPSA) ≤14 to DAPSA >14 in PsA. The area under the curve (AUC) of the sum score of deteriorated PROMs was evaluated. Results 4594 RA and 1154 PsA visits were evaluated and active disease occurred in 358 (8%) RA and 177 (15%) PsA visits. In both RA and PsA, a deterioration in general health (VAS), HAQ-DI, EQ-5D and pain (VAS/NRS) was significantly associated with active disease. The combination of these PROMs showed acceptable to excellent discriminative ability (RA AUC=0.76, PsA AUC=0.85). If a cut-point of ≥1 deteriorated PROMs is used, 40% of the visits in which RA patients have remission or low disease activity are correctly specified (specificity of 40%), while 10% of visits with active disease are overlooked (sensitivity of 90%). In PsA, these percentages are 41% and 4%, respectively. Conclusion A combination of general health, HAQ-DI, EQ-5D and pain could aid as a screening tool for active disease in patients with RA and PsA. These data could help facilitate remote monitoring of RA and PsA patients in the future. Trial registration numbers ISRCTN26791028, NTR2754.
Open AccessCombining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritis
Objectives To investigate whether a combination of general health (Visual Analogue Scale (VAS)), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain (VAS/Numerical Rating Scale (NRS)), quality of life (EQ-5D), fatigue (VAS/NRS) and presenteeism (0%–100% productivity loss) could aid as a screening tool to detect active disease in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Methods RA patients from the tREACH trial and TARA trial (n=683) and PsA patients from the DEPAR cohort (n=525) were included. The association of a deterioration in the aforementioned patient-reported outcome measure (PROM) scores between two consecutive visits and having active disease was assessed. Active disease was defined as a change from disease activity score (DAS) ≤2.4 to DAS >2.4 in RA or Disease Activity Index in Psoriatic Arthritis (DAPSA) ≤14 to DAPSA >14 in PsA. The area under the curve (AUC) of the sum score of deteriorated PROMs was evaluated. Results 4594 RA and 1154 PsA visits were evaluated and active disease occurred in 358 (8%) RA and 177 (15%) PsA visits. In both RA and PsA, a deterioration in general health (VAS), HAQ-DI, EQ-5D and pain (VAS/NRS) was significantly associated with active disease. The combination of these PROMs showed acceptable to excellent discriminative ability (RA AUC=0.76, PsA AUC=0.85). If a cut-point of ≥1 deteriorated PROMs is used, 40% of the visits in which RA patients have remission or low disease activity are correctly specified (specificity of 40%), while 10% of visits with active disease are overlooked (sensitivity of 90%). In PsA, these percentages are 41% and 4%, respectively. Conclusion A combination of general health, HAQ-DI, EQ-5D and pain could aid as a screening tool for active disease in patients with RA and PsA. These data could help facilitate remote monitoring of RA and PsA patients in the future. Trial registration numbers ISRCTN26791028, NTR2754.
- Open Access
Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort
Objective Persistent articular inflammation in psoriatic arthritis (PsA) is associated with radiographic damage. Despite advances in diagnosis and therapy, radiographic structural damage remains prevalent in PsA. To elucidate this topic, we studied which baseline clinical characteristics determine radiographic progression. Methods For this analysis, data were used from DEPAR (Dutch South West Psoriatic Arthritis) Study, a real-world cohort of patients with newly diagnosed PsA. Radiographic changes were assessed using the modified Total Sharp/van der Heijde Score (mTSS) for PsA. Univariable–multivariable mixed-effects negative binomial regression analysis was applied to define baseline predictors for radiographic progression over time. Results The study included 476 patients with early PsA with 1660 hand and feet radiographs from four different time points (baseline, first, second and third year). The progressive group (n=71) had a higher mTSS compared with the non-progressive group (n=405) at diagnosis (17 (3–36) vs 0 (0–1)). A comparison of the two groups revealed that the progressive group had significantly older (59 (12) vs 49 (13)) and a higher rate of the presence of swollen joints (93% vs 78%) at diagnosis. Multivariable analysis identified age (incidence rate ratio (IRR)=1.10, p=0.000), sex (female) (IRR=0.48, p=0.043) and baseline mTSS (IRR=1.11, p=0.000) as significant determinants of radiographic change over time. For the progressive subset, additionally, the multivariable analysis highlighted baseline Disease Activity in PSoriatic Arthritis (IRR=1.05, p=0.006) and swollen joint count (IRR=1.07, p=0.034) as predictors. Conclusions According to this real-world cohort, patients with early PsA exhibit minimal radiographic progression under current treatment protocols. This study indicates that while old age and initial radiographic damage predict progression, female sex confers a protective effect on it. Furthermore, disease activity score and swollen joints emerged as predictors for radiographic changes during the follow-up in progressive patients.
Open AccessDeterminants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort
Objective Persistent articular inflammation in psoriatic arthritis (PsA) is associated with radiographic damage. Despite advances in diagnosis and therapy, radiographic structural damage remains prevalent in PsA. To elucidate this topic, we studied which baseline clinical characteristics determine radiographic progression. Methods For this analysis, data were used from DEPAR (Dutch South West Psoriatic Arthritis) Study, a real-world cohort of patients with newly diagnosed PsA. Radiographic changes were assessed using the modified Total Sharp/van der Heijde Score (mTSS) for PsA. Univariable–multivariable mixed-effects negative binomial regression analysis was applied to define baseline predictors for radiographic progression over time. Results The study included 476 patients with early PsA with 1660 hand and feet radiographs from four different time points (baseline, first, second and third year). The progressive group (n=71) had a higher mTSS compared with the non-progressive group (n=405) at diagnosis (17 (3–36) vs 0 (0–1)). A comparison of the two groups revealed that the progressive group had significantly older (59 (12) vs 49 (13)) and a higher rate of the presence of swollen joints (93% vs 78%) at diagnosis. Multivariable analysis identified age (incidence rate ratio (IRR)=1.10, p=0.000), sex (female) (IRR=0.48, p=0.043) and baseline mTSS (IRR=1.11, p=0.000) as significant determinants of radiographic change over time. For the progressive subset, additionally, the multivariable analysis highlighted baseline Disease Activity in PSoriatic Arthritis (IRR=1.05, p=0.006) and swollen joint count (IRR=1.07, p=0.034) as predictors. Conclusions According to this real-world cohort, patients with early PsA exhibit minimal radiographic progression under current treatment protocols. This study indicates that while old age and initial radiographic damage predict progression, female sex confers a protective effect on it. Furthermore, disease activity score and swollen joints emerged as predictors for radiographic changes during the follow-up in progressive patients.